profit warn potenti impair come myx issu trade
gener product
perform sinc result due increas competit key
product one-off advers item addit high margin
specialti brand revenu weaker expect softer sorilux
growth ytd group revenu declin vs pcp jan-apr
gross profit declin myx current review carri
valu gener asset could result impair
liothyronin experienc sale declin yoy
greenston launch gener product end march impact
price immedi accord script data greenston captur
share myx dofetilid also seen increas competit
forecast gener product sale gross profit
limit improv full-year impact
price eros off-set two new licenc agreement commenc
ebitda recov forecast ebitda
return level tolsura like take time get
onto formulari us hospit signific earn contribut
unlik addit myx launch gener nuvar
expect key competitor dr reddi teva expect
downgrad neutral outperform tp reduc
due ebitda ep downgrad
forecast period factor weaker outlook gener busi
continu see merit myx strategi pivot toward
stabl earn profil specialti brand portfolio outlook
remain unclear uncertainti around new product ramp-up increas
competit key product gener portfolio
valuat metric
chang previou ep
outperform neutral
price month
total return forecast perspect
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price book
return equiti
return asset
return invest cap
net debt ebitda
capital-expenditure sale
capital-expenditure depr
price may rate outperform neutral target price analyst gretel janu
profit tax
profit tax
unusu item tax
chang work capit
cash non-cash item
movement cash/equival
 asx close
spot exchang rate
profit warn rebas assumpt
myx issu trade updat profit warn cite signific deterior
gener product perform sinc result group revenu declin
vs pcp jan-apr gross profit declin go detail
factor drive weaker perform
despit weak jan-april may june season stronger month
manag expect busi see rebound final two trade
month forecast slight improv may-jun gener product
revenu yoy vs jan-apr period manag provid
guidanc
figur highlight updat forecast group revenu group gross
profit versu ytd perform forecast group gross profit flat vs prior
year forecast ebitda yoy due higher expens
increas sale market forc due new product launch
figur myx trade updat gener deterior jan-april
compani data credit suiss estim result includ abnorm doryx return
follow myx market updat made number adjust model
assumpt result averag ebitda downgrad across forecast
period averag ep downgrad
increas level price eros key gener product liothyronin
dofetilid given increas competit addit price eros
forecast myx lose market share given new product launch space
decreas ramp-up tolsura suba-itraconazol given slower up-tak
us hospit previous forecast
decreas sorilux revenu growth weaker ytd trade perform
result chang dcf valuat decreas per share
continu see merit myx strategi pivot toward
stabl earn profil specialti brand portfolio outlook remain
unclear limit new product off-set increas competit gener
figur myx trade histor price-to-earnings
figur premium market
myx price-to-earnings rel industri ex-financi
forecast divis
gener product sale first four month
pcp driven competit pressur key product
dofetilid sale decreas pcp competit affect
volum price
liothyronin sale pcp greenston launch
gener liothyronin end march price immedi impact
point myx expect addit competit liothyronin
myx sale affect addit competit aurobindo launch
figur new competit liothyronin
one-off item impact period includ failure-
to-suppli penalti result larg supplier unabl deliv product time
shelf stock adjust result price chang expect repeat
gener product gross profit margin fell period
first half adjust one-off item gross profit margin would
forecast gener product sale yoy
forecast gener product sale factor
declin liothyronin sale price eros rest busi off-set
two new licenc agreement commenc two new product market
gener equival today two market brand iqvia sale
potenti suppli disrupt still like happen potenti
player market could becom player market factor potenti upsid
number
forecast gener nuvar launch
specialti brand sale pcp first four month
growth across key product fabior sorilux
doryx famili usd term
launch lexett halobetasol februari also contribut growth
total prescript exceed latest week data
forecast specialti brand product sale yoy
forecast specialti brand product sale yoy benefit
full-year impact tolsura lexett continu growth fabior sorilux
metric contract servic sale first four month
yoy driven grow commerci manufactur revenu later
pipelin commerci manufactur opportun remain attract
commerci manufactur quot issu expect becom
approv supplier eight market applic come year
forecast sale yoy expand
mayn pharma intern report revenu first four month
pcp benefit grow sale itraconazol global
addit third parti contract develop manufactur servic
forecast mpi sale yoy expand
given prevail us gener market condit outlook compani
perform detail review carri valu gener acquir
develop intang asset full year end june
hand april higher posit
decemb payment commerci launch lexett
compani bank debt remain consist decemb balanc
compani continu signific headroom bank coven
good sold
depreci asset
amortis
profit tax
figur gener product largest segment
revenu contribut divis
revenu contribut divis mn
figur weaker earn
figur margin
gross margin segment
figur gpd declin
chart compani data credit suiss estim
new total return forecast perspect chart help visual credit suiss consensu view compani return within
context forecast risk histor trade pattern
volatil calcul annualis standard deviat weekli total return seri past month illustr variabl
stock return word risk way think one would rather take forecast return stock volatil
stock volatil shade area show one standard deviat rang base past month volatil statist
term make number brave assumpt probabl share price end insid rang month
hi-lo maximum minimum daili close price past week often handi know price momentum especi
stock trade close high low stock trade close peak momentum stock
consensu consensu suppli thomson reuter survey sell side research analyst collect dozen data
point ep dp sale target price roe mean averag target return shade area around mean
repres rang estim lowest highest estim aid visualis number import factor rang
analyst estim credit suiss estim stock sit rel consensu share price rel consensu
mean consensu rang target
return calcul capit gain plu forecast dividend yield net next month cs tgt use credit suiss
target price credit suiss forecast forward dividend gross frank consensu mean rang use
consensu target price consensu dividend forecast month forward
compani mention price
